Presentation is loading. Please wait.

Presentation is loading. Please wait.

TC 1600 Biotechnology and Pharmaceutical Customer Partnership Meeting John Doll - Commissioner for Patents November 10, 2005.

Similar presentations


Presentation on theme: "TC 1600 Biotechnology and Pharmaceutical Customer Partnership Meeting John Doll - Commissioner for Patents November 10, 2005."— Presentation transcript:

1 TC 1600 Biotechnology and Pharmaceutical Customer Partnership Meeting John Doll - Commissioner for Patents November 10, 2005

2 2 Contact Information John Doll Commissioner for Patents Phone:

3 Application Filings and and Examiner Production Examiner Production

4 4 UPR Applications Filed FY 05 plan 375,080 (7% above FY 04) 383,000 as of 10/30/05 (preliminary) Current projection 1.7% over plan

5 5 FY 04 FY 05 Target FY 05 UPR 1 FAOM 2 288,315297,614297,287 UPR Disposals 3 287,188295,456279,345 UPR Production Units 4 287,752296,535288,316 PCT Production Units 5 16,88222,91615,147 Production 1 UPR = Utility, Plant, and Reissue Applications. 2 FAOM = First Action on the Merits – first action count by an examiner after the filing of an application (does not include restrictions or other miscellaneous actions). 3 Disposal = An examiner allowance, abandonment, or disposals following a board decision. 4 Production Unit = First action count plus disposal count divided by 2. 5 PCT = Patent Cooperation Treaty. PCT applications are processed differently and tracked separately from US National stage applications. For FY 05, 15,147 PUs is 35,389 processed applications.

6 ... vs the Backlog PENDENCY

7 7 FY 05 Patent Pendency (as of 10/1/2005) FY 05 Patent Pendency (as of 10/1/2005) Technology Center Average 1 st Action Pendency (months) 1 Average Total Pendency (months) Biotechnology and Organic Chemistry Chemical and Materials Engineering Computer Architecture Software and Information Security – Communications Semiconductor, Electrical, Optical Systems Transportation, Construction, Electronic Commerce Mechanical Engineering, Manufacturing and Products UPR Total (as of 10/1/2005) FY 05 Target 20.7* Average 1 st action pendency is the average age from filing to first action for a newly filed application, completed during July-September FY Average total pendency is the average age from filing to issue or abandonment of a newly filed application, completed during July-September FY * Assuming current input and output estimates, the agency should achieve first action pendency of 21.3 months by the end of FY 2005 and total pendency of 30.2 months.

8 8 First Action Pendency by Art Areas High Pendency Art Areas Pendency 1 (months) Low Pendency Art Areas Pendency 1 (months) 1640 – Immunology, Receptor/ Ligands, Cytokines, Recombinant Hormones, and Molecular Biology – Heterocyclic Compounds and Uses – Distillation, Mineral Oil and Hydrocarbons – Radiation Imagery – Simulation and Modeling, Emulation of Computer Components – Manufacturing Control Systems and Chemical/ Mechanical/Electrical Control – Interactive Video Distribution – General Electrical Communication – Control Circuits – Electrical Connectors – Finance & Banking, Accounting – Animal and Plant Husbandry – Body Treatment, Kinestherapy, and Exercising – Thermal Combustion Technology Average 1 st action pendency is the average age from filing to first action for a newly filed application, completed during July-September FY 2005.

9 9 Inventory by Art Examples High Inventory Art Areas Months of Inventory* Low Inventory Art Areas Months of Inventory* 1614, 1615, and 1617 – Drugs, Bio-affecting and Body Treatment – Organic Chemistry – Radiation Imagery – Adhesive Bonding and Coating Apparatus – Computer Task Management – Manufacturing Control Systems and Chemical/ Mechanical/Electrical Control – Interactive Video Distribution , 2653 – Information Storage and Retrieval – Control Circuits – Electrical Conductors – Business Methods27 – – Conveying and 3737 – Medical Instruments, Diagnostic Equipment – Thermal and Combustion Technology 8 * The number of months it would take to reach a first action on the merits (e.g., an action addressing patentability issues) on a new application filed as of Jan 2005 at todays production rate. Todays production rate means that there are no changes in production due to hiring, attrition, changes to examination processing or examination efficiencies, and that applications are taken up in the order of filing in the given art unit/area. Of course, USPTO is taking aggressive steps to ensure changes that will significantly lower the inventory rates in high-inventory art areas.

10 Total*Design New Applications 1 9/30/ ,40263,92371,77897,38077,65156,73865,005508,87818,451 New Applications 1 9/30/ ,64472,69776,529115,58594,42570,35483,225586,58024,056 Overall Pending Applications 2 9/30/ ,006105,447102,440138,822137,458101,097108,039809,32327,599 Overall Pending Applications 2 9/30/ ,647120,767117,728167,721159,687117,045130,168932,30037,607 TC Application Inventory 1 New Application inventory is the number of new applications designated or assigned to a technology center awaiting a first action. 2 Overall Pending Application inventory is the total number of applications designated or assigned to a technology center in an active status. Includes new applications; rejected awaiting response; amended; under appeal or interference; suspended; reexams and allowed applications awaiting grant publication. *Total inventory includes applications not assigned to a particular TC, awaiting processing either pre- or post-examination.

11 11 Pendency Achieved Target 30.2 Months Target 21.3 Months

12 Patent Quality (Shared Responsibility)

13 13 Quality of Products – FY 05 Fiscal Year 2005 FY Desig n FY 05 FY 05 Target Patent In-Process Examination Compliance Rate 1* 82.0%81.7%82.9%88.1%84.7%90.9%84.4%86.6%94.3%86.2%84.0% Patent Allowance Error Rate 2* 5.32%4.88%6.46%3.56%2.25%4.43%4.94%6.43%1.6%4.55%4.0% *Compliance and error rates as measured by OPQA. 1 Compliance is the percent of office actions reviewed and found to be free of any in-process examination deficiency (an error that has significant adverse impact on patent prosecution). 2 Patent allowance error rate is the percent of allowed applications reviewed having at least one claim which is considered unpatentable on a basis for which a court would hold a patent invalid. Allowance occurs before a patent is issued, so these errors are caught before any patent is actually granted.

14 14 Percent of Allowed Applications with Material Defect Target 4%

15 Re-Work

16 16 Technology Centers Rework* Statistics * Rework first actions are those actions that are in a Continuing (CONs and CIPs), RCE, CPA or 129(a) applications (excludes Divisionals).

17 Hiring and Retention

18 18 Hires and Attritions CorpsDesign FY 04 Hires FY 04 Attritions FY 05 BOY Examiner Staff FY 05 Hiring (10/1/05) FY 05 Attrits (10/1/05) FY 05 Hiring Goal New Hires as a Percent of Examiner Staffing in the TC 24%13%40%26%25%22%30%26%

19 19 FY 05 Attrition of Average Staff

20 Pendency Projections

21 HistoricWithout Strategic Plan

22 HistoricWithout Strategic Plan 1,000 Hires & Low Attrits

23 HistoricWithout Strategic Plan 1,000 Hires & Low AttritsPlus Claims & Continuation Limits

24 HistoricWithout Strategic Plan1,000 Hires & Low AttritsPlus Claims & Continuation LimitsPlus Patentability Report

25

26 Production

27 27

28 Stats and Stuff

29 29 Continuation* Applications Filed *Straight Continuations 37 CFR §1.53 (b)(1) – No Divisionals or CIPs – as of 10/23/05

30 30 RCE/CPA Filing Rates as of 10/23/05

31 31 Total Continuation Filing Rates *Straight Continuations 37 CFR §1.53 (b)(1) – No Divisionals or CIPs – as of 10/23/05

32 32 Total Continuation* Filing Rates *Continuation = Straight Continuations 37 CFR §1.53 (b)(1) + RCE + CPA – Not Divisionals or CIPs as of 10/23/05

33 33 Continuation Filing Rates

34 34 As of 10/24/2005

35 35 Distribution of Independent Claims at Filing

36 36 TC 1600 Distribution of Independent Claims at Filing

37 37 Distribution of Total Claims at Filing

38 38 TC 1600 Distribution of Total Claims at Filing

39 39 Total Claims at Filing and Issue

40 40 Distribution of the Number of References Cited in Applications

41 Markush Practice

42 42 1.A cell adhesion protein of formula (1), A-(B)-(C)-(D) n -E or a pharmaceutically acceptable derivative thereof, wherein...

43 Accelerated Examination Would You Like Your Patent In 12 Months ?!?

44 44 Accelerated Examination Features of the proposed revision: Features of the proposed revision: Move to the head of the line Move to the head of the line Final Disposition within 12 months Final Disposition within 12 months Program for expedited Issuance of Patents Program for expedited Issuance of Patents e-file application and all follow on papers e-file application and all follow on papers Single Invention Single Invention Limited Number of Claims Limited Number of Claims Patentability Report Patentability Report Possible Interview before 1 st Action Possible Interview before 1 st Action Shortened Statutory Period Shortened Statutory Period Enforcement of special status in the Corps Enforcement of special status in the Corps

45 45 Contact Information John Doll Commissioner for Patents Phone:


Download ppt "TC 1600 Biotechnology and Pharmaceutical Customer Partnership Meeting John Doll - Commissioner for Patents November 10, 2005."

Similar presentations


Ads by Google